The estimated Net Worth of Sanjay Nayak is at least $1.52 Milhão dollars as of 23 August 2024. Sanjay Nayak owns over 1,832 units of Ocular Therapeutix Inc stock worth over $1,487,077 and over the last few years Sanjay sold OCUL stock worth over $29,805.
Sanjay has made over 2 trades of the Ocular Therapeutix Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Sanjay sold 1,832 units of OCUL stock worth $16,525 on 23 August 2024.
The largest trade Sanjay's ever made was selling 2,274 units of Ocular Therapeutix Inc stock on 23 May 2024 worth over $13,280. On average, Sanjay trades about 1,369 units every 31 days since 2024. As of 23 August 2024 Sanjay still owns at least 176,194 units of Ocular Therapeutix Inc stock.
You can see the complete history of Sanjay Nayak stock trades at the bottom of the page.
Sanjay's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD, MA, 01730.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer, eVenture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: